Publications

Background The PD-L1 combined positive score (CPS) is a widely used but imperfect biomarker in head and neck squamous cell carcinoma (HNSCC). The Immune Profile Score (IPS), Tempus’ AI-developed multi-modal biomarker integrating genomics and transcriptomics, offers a potentially more nuanced alternative.

Background EO-PCa is increasingly recognized as a biologically distinct entity, but its clinical behavior, molecular features, and outcomes relative to LO-PCa are incompletely characterized. Methods The Tempus Lens Platform (Tempus AI, Inc., Chicago, IL) was used to query the de-identified, multimodal database for patients (pts) diagnosed with metastatic prostate cancer (N= 6,967) tested with Tempus xT (DNA-seq) and xR (RNA-seq).

Background T-DXd, a HER-2 targeted antibody drug conjugate, received tumor agnostic approval for HER2-expressing (IHC 3+) tumors based on the results from the DESTINY-PanTumor02 trial. Despite rapid clinical adoption in gynecologic cancers, real world data remains limited. We sought to assess the real-world outcomes of T-DXd in patients with gynecologic cancers.

Background The PDJ amplicon contains three functionally linked, druggable genes (PD-L1, PD-L2, and JAK2), but the impact of its expression on IO response in TNBC has not been well-characterized. Methods The Tempus Lens Platform was used to identify patients (pts) diagnosed with metastatic TNBC (mTNBC) who underwent clinical sequencing using the Tempus xT (DNA) and xR (RNA) assays.

Background Preclinical studies show that the amino acid stress-sensing kinase GCN2 (EIF2AK4) is constantly active and essential for growth in hormone-sensitive (HSPC) and castration-resistant prostate cancer (CRPC) models. However, the significance of GCN2 expression in advanced prostate cancer (PCa) remains unclear.

Introduction VEGF family signaling shapes angiogenesis and immune regulation in NSCLC; however, ligand/isoform-specific effects on (chemo)IO outcomes remain unclear. Methods TEMPUS clinicogenomic data (2011-2025) were evaluated for patients with metastatic NSCLC treated with frontline chemoIO, IO, or chemo.

Background Timely identification of actionable biomarkers in NSCLC patients improves outcomes; however, guideline-recommended NGS-based testing and IHC testing rates remain low. Rapid pre-screening of routine hematoxylin and eosin (H&E) WSI at the time of diagnosis could facilitate follow-through testing and equitable access to timely treatment.

Background ATM germline mutation carriers have a two-fold increased risk of ovarian cancer, but little is known about tumor biology and outcomes of ATM-associated ovarian cancer. Methods Using the Tempus Lens Platform, we identified ovarian cancer patients tested with Tempus xT (DNA, 648 genes), tumor-normal match testing, and receipt of 1L platinum-based therapy.

Background Early onset breast cancer (EOBC; ≤ 45 years) is a growing public health challenge and the leading cause of cancer-death in young women. While next-generation sequencing (NGS) has expanded genomically targeted therapy approvals, outcomes in EOBC remain worse than non-EOBC. This study characterized the genomic landscape of EOBC.

Background PTEN alts confer aggressive biology, yet targeting the PI3K–AKT pathway has yielded inconsistent results. Prior studies relied on PTEN IHC and did not account for PTEN alt subtype, PI3K pathway alt burden, or molecular lineage. We hypothesized the prognostic impact of PTEN alt depends on alt subtype, concurrent PI3K pathway alt and ERG lineage.